This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Spark Tries to Quell Investor Fears About Gene Therapy Test

Spark Therapeutics provided details Thursday about changes made to a clinical trial involving the company's gene therapy, trying to calm jittery biotech investors before study results next month.

Biogen Takes on Celgene With New Autoimmune License Deal

Biogen stepped into the oral S1P modulator race Wednesday with the acquisition of a license to develop a mid-stage compound from Japan's Mitsubishi Tanabe Pharma.

Santhera Drug Wins European Approval for Rare Blindness Disease

The Santhera drug, Raxone, is the first approved treatment for Leber hereditary optic neuropathy (LHON), which affects approximately 10,000 patients in Europe.

Tuesday's Clinical Trial Scorecard: Akebia Wins, Tetraphase, Flexion, Theravance Lose

Four biotech companies announced important clinical trials results Tuesday at market close.

Global Blood Valuation Gives Goldman Analyst Pause

Sell-side cheerleading on behalf of their employer's banking clients has become such a standard practice that anything remotely bearish is news.

Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Sage Psychiatric Drug Shows Activity Hint in Small Muscle Tremor Study

The signal of activity Sage Therapeutics sees with SAGE-547 in essential tremor may turn out to be real or a mirage.

The Numbers Behind Biotech's Horrible, No Good, Awful August

Among all U.S.-listed biotech stocks, regardless of market cap, only 68 companies managed to end August with higher stock prices, while 267 biotech stocks lost ground.

Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to Pipeline

Acquiring Scioderm gives Amicus another late-stage orphan disease drug expected to have pivotal trial data in the first half of next year.

Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews

Approving both the Biomarin and Sarepta drugs for Duchenne muscular dystrophy is the most politically expedient decision the FDA can make.

Page 3 of 343
Top Rated Stocks Top Rated Funds Top Rated ETFs